Silencing METTL14 mitigated the inhibitory effects of sorafenib on tumor growth, whereas silencing FTH1 significantly increased sorafenib’s efficacy in suppressing tumor growth, thereby counteracting the effects of METTL14 silencing (Figure 6(a–c)). Here, METTL14 is linked to neoplasm.